CKPTCheckpoint Therapeutics, Inc.

Nasdaq checkpointtx.com


$ 2.26 $ -0.02 (-0.66 %)    

Monday, 26-Aug-2024 15:59:51 EDT
QQQ $ 474.46 $ -4.66 (-0.97 %)
DIA $ 412.48 $ 0.89 (0.22 %)
SPY $ 560.78 $ -1.34 (-0.24 %)
TLT $ 98.13 $ -0.25 (-0.25 %)
GLD $ 232.75 $ 0.74 (0.32 %)
$ 2.25
$ 2.20
$ 2.25 x 400
-- x --
$ 2.17 - $ 2.26
$ 1.30 - $ 3.62
307,447
na
101.29M
$ 1.30
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-10-2024 03-31-2024 10-Q
3 03-22-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-31-2023 12-31-2022 10-K
8 11-10-2022 09-30-2022 10-Q
9 08-12-2022 06-30-2022 10-Q
10 05-12-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-06-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 03-12-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-11-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-10-2019 03-31-2019 10-Q
23 03-18-2019 12-31-2018 10-K
24 11-02-2018 09-30-2018 10-Q
25 08-07-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-16-2018 12-31-2017 10-K
28 11-03-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 03-17-2017 12-31-2016 10-K
32 11-14-2016 09-30-2016 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-maintains-buy-on-checkpoint-therapeutics-lowers-price-target-to-20

HC Wainwright & Co. analyst Joseph Pantginis maintains Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and lowers the p...

 checkpoint-therapeutics-q2-eps-018-beats-030-estimate-sales-4100k-beat-2000k-estimate

Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate ...

 checkpoint-therapeutics-says-fda-accepted-for-review-its-resubmission-of-its-biologics-license-application-for-cosibelimab

Cosibelimab is its anti-programmed death ligand-1 ("PD-L1") antibody, as a potential new treatment for adults with meta...

 hc-wainwright--co-reiterates-buy-on-checkpoint-therapeutics-maintains-34-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and maintains $...

Core News & Articles

Collaboration explores the potential synergistic effects of Checkpoint's anti-PD-L1, cosibelimab, in combination with the a...

 checkpoint-therapeutics-announces-12m-registered-direct-offering-of-5853659-shares-of-its-common-stock-at-a-purchase-price-of-205-per-share-priced-at-the-market-under-nasdaq-rules

Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology compan...

 checkpoint-therapeutics-resubmits-bla-for-cosibelimab-to-fda-for-advanced-skin-cancer-treatment

Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a clinical-stage immunotherapy and targeted oncology compan...

 hc-wainwright--co-reiterates-buy-on-checkpoint-therapeutics-maintains-34-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and maintains $...

 hc-wainwright--co-reiterates-buy-on-checkpoint-therapeutics-maintains-34-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and maintains $...

 checkpoint-therapeutics-q1-eps-033-misses-027-estimate

Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.33) per share which missed the analyst consensus estimat...

 hc-wainwright--co-reiterates-buy-on-checkpoint-therapeutics-maintains-34-price-target

HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and maintains $...

 checkpoint-therapeutics-fy23-eps-317-vs-709-yoy-as-of-december-31-2023-checkpoints-cash-and-cash-equivalents-totaled-49m

Financial Results: Cash Position: As of December 31, 2023, Checkpoint's cash and cash equivalents totaled $4.9 million, ...

 pinterest-checkpoint-therapeutics-and-2-other-stocks-insiders-are-selling

The Nasdaq 100 closed higher by around 300 points on Friday. Investors, meanwhile, focused on some notable insider trades.

 b-riley-securities-maintains-buy-on-checkpoint-therapeutics-lowers-price-target-to-4-report-released-on-19th-december-2023

B. Riley Securities analyst Mayank Mamtani maintains Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and lowers the price t...

 b-riley-securities-maintains-buy-on-checkpoint-therapeutics-lowers-price-target-to-4

B. Riley Securities analyst Mayank Mamtani maintains Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and lowers the price t...

 why-compugen-shares-are-trading-higher-by-over-200-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with t...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION